This topic contains a solution. Click here to go to the answer

Author Question: The short-term application of inspiratory positive pressure to a spontaneously breathing patient ... (Read 32 times)

SGallaher96

  • Hero Member
  • *****
  • Posts: 509
The short-term application of inspiratory positive pressure to a spontaneously breathing patient best defines which of the following?
 
  a. Sustained maximal inspiration
  b. Intermittent positive-pressure breathing
  c. Continuous positive airway pressure
  d. Positive end-expiration pressure

Question 2

Which of the following is FALSE about flow-oriented incentive spirometry devices?
 
  a. Inspired volume is estimated as the prod-uct of flow and time.
  b. Motivation is based on keeping the indi-cator balls elevated.
  c. They have proved less effective than volumetric systems.
  d. They provide only an indirect measure of inspired volume.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

jasonq

  • Sr. Member
  • ****
  • Posts: 335
Answer to Question 1

ANS: B
Intermittent positive-pressure breathing refers to the application of inspiratory positive pressure to a spontaneously breathing patient as an intermittent or short-term therapeutic modality.

Answer to Question 2

ANS: C
No evidence to date indicates that one type is more beneficial than the other.




SGallaher96

  • Member
  • Posts: 509
Reply 2 on: Jul 16, 2018
YES! Correct, THANKS for helping me on my review


abro1885

  • Member
  • Posts: 337
Reply 3 on: Yesterday
Thanks for the timely response, appreciate it

 

Did you know?

About 100 new prescription or over-the-counter drugs come into the U.S. market every year.

Did you know?

About one in five American adults and teenagers have had a genital herpes infection—and most of them don't know it. People with genital herpes have at least twice the risk of becoming infected with HIV if exposed to it than those people who do not have genital herpes.

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

Did you know?

More than 34,000 trademarked medication names and more than 10,000 generic medication names are in use in the United States.

Did you know?

This year, an estimated 1.4 million Americans will have a new or recurrent heart attack.

For a complete list of videos, visit our video library